Hepatitis B Surface Antibody, Quantitative, HBIG Assessment
Also known as: Anti-HBs, Antibody to Hepatitis B Surface Antigen, HBV
Use
This test is designed for use in assessing therapy with HBIG for patients who have had a liver transplant.
Special Instructions
Not provided.
Limitations
Presence of anti-HBs is not an absolute indicator of resolved hepatitis infection nor of protection from future infection. Since there are different serologic subtypes of hepatitis B virus, it is possible (and has been reported) for a patient to have antibody to one surface antigen type and to be acutely infected with a virus of a different subtype. Thus, a patient may have coexisting HBsAg and anti-HBs. Transfused individuals or hemophiliacs receiving plasma components may have false-positive results for antibody to hepatitis B surface antigen.
Methodology
Immunochemiluminometric assay (ICMA). Samples will be diluted and titered to endpoint.
Biomarkers
LOINC Codes
- 16935-9
- 16935-9
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Unknown
Volume
Not provided
Minimum Volume
Not provided
Causes for Rejection
Non-EDTA plasma specimen; PST gel-barrier tube